BUY HOLD SELL – Qantas (ASX: QAN)Last week Marcus sold down his (ASX: QAN) holding in the MP growth portfolio, we still have a 1.5% position and have discussed what conditions we would want to see before topping that up. Today’s article explores that idea. Vaccine optimism has been largely overshadowed by the deteriorating virus picture and the US election. With 10-vaccines in phase three trials, hopes are rising for approval by the end of the year. So, what stock is likely to re-rate strongly should a vaccine be crowned? Qantas (ASX: QAN) arguably has that potential and while revenues will take a long time to reach pre-pandemic levels, we know the market will move quickly on the prospect of COVID-normal air travel. Even with a vaccine, it should be acknowledged that the time frame for a return to full capacity is in years, given the practical side of inoculating an entire population. Criticism of QAN’s investment case points to possible waning enthusiasm once that issue becomes more apparent and the initial hype has worn-off. The other tailwind for QAN is the improving picture on the local front. News of Victoria’s relaxed restrictions and the potential re-opening of state borders prior to Christmas, paving the way for increased revenues. NSW Premier Gladys Berejiklian today announced that NSW will reopen its borders to Victoria from 12.01 am on November 23. Alan Joyce talked about the need for reinvention at the company’s AGM last month. The business is, without question, going to be structurally different to the pre-COVID flying kangaroo we knew. Flying Joey perhaps? At least for a while. $15bn in cost savings over the next three years, mainly through reduced flying activity, with $1bn in ongoing cost improvements from FY23 some of the headline numbers. The delay in border reopening has also come at a cost, ~$100m negative hit to earnings for the first quarter of FY21. QAN had expected to be at 60% pre-pandemic domestic capacity by now. That said, its three-year recovery plan remains on track. Anticipating a boom in domestic tourism once restrictions are eased further. Forecasting domestic market share to grow from 60 to 70% now that virgin is changing its strategy.
- This financial year is going to be a throwaway for QAN, ROE forecast to be minus 98.8%. A much more palatable 14% is expected to return in FY22.
- Revenue and EPS growth will be non-existent as it transitions to a smaller business. FY2 and FY3 are forecast to be much more normal.
- Of the 11 brokers surveyed by Thomson Reuters 73% have a buy or strong buy recommendation, it is trading at a 6.5% discount to the average target price.
SHORT TERM TECHNICAL OVERVATIONS Since the March low QAN is up ~120%. The stock found a bottom at 320c in the lead up to its result on August 20. QAN is up ~20% since releasing its full-year report. RSI is elevated although not yet in overbought territory. What is interesting to note is the high in June ~500c. Going off the broker target prices, it's likely they see 500c as a possible resistance level which will be hard to break. The stock will have to climb 12% before we find out. Macquarie the most bullish of the brokers with a 495c price target. None of them, however, commented on vaccine optimism and the potential catalyst that would provide to the share price. The stock has also printed a 3MA buy signal.
TOP SHAREHOLDERS QAN is not finding favor amongst its largest owners, BlackRock offloading more than 26m shares at the end of September. Vanguard dipped its toes in a bit more at the same time, along with US Global Investors but nothing significant.
SHORTING QAN’s short interest has fluctuated quite a bit over the past 12 months, currently at 2.04% - a 12-month high. Interesting to think some people see it in a worse position now compared to the start of the year, when there was more uncertainty. While the trend from July isn’t pleasing, short interest isn’t at a level to be concerned with. On the bullish side of the argument, it adds more fuel to a possible short squeeze.